In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.

AUTOR(ES)

Perfect, J R

RESUMO

Multiple isolates of Cryptococcus neoformans were tested to compare the in vitro activity of a new triazole, SCH56592, with those of amphotericin B, fluconazole, and itraconazole, MICs of each drug were determined, and minimum fungicidal concentrations of SCH56592 and amphotericin B were measured. MICs of SCH56592 were lower than those of amphotericin B and fluconazole but not those of itraconazole. Minimum fungicidal concentrations of SCH56592 were lower than those of amphotericin B. SCH56592 in the presence of human serum produces an in vitro fungicidal effect for Cryptococcus neoformans. The data indicate that SCH56592 might exert fungicidal as well as inhibitory properties in vivo. On the basis of these results, SCH56592 was evaluated with a rabbit model of experimental cryptococcal meningitis; SCH56592 treatment was compared with treatment with fluconazole. Despite no detectable drug concentrations in the cerebrospinal fluid, the activity of SCH56592 against C. neoformans infection was equivalent to that of fluconazole. SCH56592 has potent in vitro activity against C. neoformans and compares favorably to treatment with fluconazole for a central nervous system infection. SCH56592 should be studied for use in humans with cryptococcal infections.

Documentos Relacionados

• In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.
• In Vitro and In Vivo Efficacies of the New Triazole Albaconazole against Cryptococcus neoformans
• In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis.
• Cross-resistance to polyene and azole drugs in Cryptococcus neoformans.
• In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans.